Physician profile
Allison M Linquist
NPI 1396714994
$1,904.64
in general payments reported to CMS, 2019-2025
26 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $104 · 2021: $24.38 · 2024: $464 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $261.39 | 2024-2025 | Sotyktu |
| Revance Therapeutics, INC. | $133.31 | 2024 | Daxxify |
| Abbvie INC. | $131.42 | 2019-2025 | |
| Amgen INC. | $123.74 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $111.49 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.97 | 2019-2025 | Cabtreo |
| Lilly USA, LLC | $103.03 | 2019-2025 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $97.64 | 2019-2025 | |
| Pfizer INC. | $92.58 | 2019-2020 | |
| Galderma Laboratories, L.P. | $91.76 | 2019-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $90.86 | 2024-2025 | Dupixent, Libtayo |
| Almirall LLC | $85.96 | 2019-2025 | Klisyri |
| Ani Pharmaceuticals, INC. | $77.86 | 2025 | Sovuna, Veregen, Oxistat |
| Krystal Biotech INC | $58.45 | 2025 | Vyjuvek |
| Organon LLC | $50.40 | 2025 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $42.15 | 2025 | Sofdra |
| Celgene Corporation | $41.68 | 2019 | |
| Journey Medical Corporation | $34.66 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $32.33 | 2019 | |
| Incyte Corporation | $25.78 | 2024 | Opzelura |
| Medimetriks Pharmaceuticals, INC. | $24.38 | 2021 | |
| Paratek Pharmaceuticals, INC. | $23.93 | 2024 | Nuzyra |
| Arcutis Biotherapeutics, INC. | $20.17 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $15.64 | 2019 | |
| Mission Pharmacal Company | $13.63 | 2019 | |
| Sebela Pharmaceuticals INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Linquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.